Skip to main content
Top
Published in: Clinical Sarcoma Research 1/2020

01-12-2020 | Sarcoma | Research

The immune microenvironment of uterine adenosarcomas

Authors: Ali Mohammed Refaat Ali, Jen-Wei Tsai, Cheuk Hong Leung, Heather Lin, Vinod Ravi, Anthony P. Conley, Alexander J. Lazar, Wei-Lien Wang, Michael J. Nathenson

Published in: Clinical Sarcoma Research | Issue 1/2020

Login to get access

Abstract

Background

Uterine adenosarcoma (UA) is an extremely rare sarcoma subtype. There has been limited evaluation of the immune microenvironment in these tumors. The objective of this study is to examine and describe the immune infiltrate and PD-1/PD-L1 expression in UA and to correlate these changes in the tumor micro-environment with the overall survival status or the disease-free survival status (DFSS), respectively.

Methods

Patients (pts) treated at our center from 1982 to 2014 with UA were identified. Fifteen cases had tumor paraffin-embedded blocks available. Immunohistochemistry studies for CD3, CD8, FOXP3, CD163, PD-1 and PD-L1 (clone 22C3) were performed. Image analysis was used to assess the density (cells/mm2), except in PD-L1, where the percentage of membranous staining on tumor cells was noted.

Results

Immune infiltrate analysis median (range) density in cells/mm2 varied broadly: CD3 178 (15–802); CD8 117 (11–661); FoxP3 4.8 (0.2–82); CD163 791 (264–1861); and PD1 5 (1–65). 3 cases had rare (1%) PD-L1 tumor membranous labeling. The reports yielded that ten pts were alive, and 5 were dead. Pts who were alive had significant higher CD3 and CD8 median densities in tumors than those who were dead (p = 0.040). There was no correlation between DFSS and CD3 or CD8 median densities. Patients who had no local recurrence had significantly higher CD3 and CD8 median densities in tumors than those who had local recurrence (p = 0.040).

Conclusions

In conclusion, this is the first report characterizing the presence of immune infiltrate and PD-1/PD-L1 expression in UA. CD3+ CD8+ T-cells density may be prognostic. The immune-responsiveness of UA needs to be further investigated in a larger study.
Literature
1.
go back to reference Nathenson MJ, et al. Uterine adenosarcoma: a review. Curr Oncol Rep. 2016;18(11):68.CrossRef Nathenson MJ, et al. Uterine adenosarcoma: a review. Curr Oncol Rep. 2016;18(11):68.CrossRef
2.
go back to reference Nathenson MJ, et al. The importance of lymphovascular invasion in uterine adenosarcomas: analysis of clinical, prognostic, and treatment outcomes. Int J Gynecol Cancer. 2018;28(7):1297–310.CrossRef Nathenson MJ, et al. The importance of lymphovascular invasion in uterine adenosarcomas: analysis of clinical, prognostic, and treatment outcomes. Int J Gynecol Cancer. 2018;28(7):1297–310.CrossRef
3.
go back to reference D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–9.CrossRef D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131–9.CrossRef
4.
go back to reference Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review. Expert Rev Anticancer Ther. 2018;18:1093–100.CrossRef Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review. Expert Rev Anticancer Ther. 2018;18:1093–100.CrossRef
5.
go back to reference Arend R, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119(2):305–8.CrossRef Arend R, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119(2):305–8.CrossRef
6.
go back to reference Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363–81.CrossRef Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363–81.CrossRef
7.
go back to reference Machida H, et al. Significance of lymph node metastasis on survival of women with uterine adenosarcoma. Gynecol Oncol. 2017;144(3):524–30.CrossRef Machida H, et al. Significance of lymph node metastasis on survival of women with uterine adenosarcoma. Gynecol Oncol. 2017;144(3):524–30.CrossRef
8.
go back to reference Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas. Oncologist. 2018;23(1):71–83.CrossRef Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas. Oncologist. 2018;23(1):71–83.CrossRef
9.
go back to reference Tawbi H. et al. Pembrolizumab (P) in patients with advanced soft tissue (STS) and Bone sarcomas (BS): Updated efficacy results of multicenter phase II study SARC028 and correlates of response. in CTOS # 2570708. 2016. Lisbon Portugla. Tawbi H. et al. Pembrolizumab (P) in patients with advanced soft tissue (STS) and Bone sarcomas (BS): Updated efficacy results of multicenter phase II study SARC028 and correlates of response. in CTOS # 2570708. 2016. Lisbon Portugla.
10.
go back to reference Ben-Ami E, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123:3285–90.CrossRef Ben-Ami E, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123:3285–90.CrossRef
11.
go back to reference George S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(2):197–204.CrossRef George S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(2):197–204.CrossRef
12.
go back to reference D’Angelo SP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65.CrossRef D’Angelo SP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65.CrossRef
13.
go back to reference Kim JR, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE. 2013;8(12):e82870.CrossRef Kim JR, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS ONE. 2013;8(12):e82870.CrossRef
14.
go back to reference Shen JK, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2(7):690–8.CrossRef Shen JK, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2(7):690–8.CrossRef
15.
go back to reference Vanderstraeten A, et al. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014;63(6):545–57.CrossRef Vanderstraeten A, et al. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014;63(6):545–57.CrossRef
16.
go back to reference Tsukahara T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97(12):1374–80.CrossRef Tsukahara T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97(12):1374–80.CrossRef
17.
go back to reference Yabe H, et al. Prognostic significance of HLA class I expression in Ewing’s sarcoma family of tumors. J Surg Oncol. 2011;103(5):380–5.CrossRef Yabe H, et al. Prognostic significance of HLA class I expression in Ewing’s sarcoma family of tumors. J Surg Oncol. 2011;103(5):380–5.CrossRef
18.
go back to reference Berghuis D, et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol. 2009;218(2):222–31.CrossRef Berghuis D, et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol. 2009;218(2):222–31.CrossRef
19.
go back to reference Kostine M, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. Oncoimmunology. 2018;7(2):e1386828.CrossRef Kostine M, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. Oncoimmunology. 2018;7(2):e1386828.CrossRef
20.
go back to reference Pollack SM, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123(17):3291–304.CrossRef Pollack SM, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123(17):3291–304.CrossRef
21.
go back to reference Woolson RF, Clarke WR. Statistical methods for the analysis of biomedical data, vol. 371. Hoboken: Wiley; 2011. Woolson RF, Clarke WR. Statistical methods for the analysis of biomedical data, vol. 371. Hoboken: Wiley; 2011.
22.
go back to reference Spearman C. The proof and measurement of association between two things. Am J Psychol. 1904;15(1):72–101.CrossRef Spearman C. The proof and measurement of association between two things. Am J Psychol. 1904;15(1):72–101.CrossRef
23.
go back to reference de Jong RA, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–10.CrossRef de Jong RA, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–10.CrossRef
24.
go back to reference Santoiemma PP, et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol. 2016;143(1):120–7.CrossRef Santoiemma PP, et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol. 2016;143(1):120–7.CrossRef
25.
go back to reference Longoria TC, Eskander RN. Immunotherapy in endometrial cancer—an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015;2:11.CrossRef Longoria TC, Eskander RN. Immunotherapy in endometrial cancer—an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015;2:11.CrossRef
26.
go back to reference Pakish JB, Jazaeri AA. Immunotherapy in gynecologic cancers: are we there yet? Curr Treat Options Oncol. 2017;18(10):59.CrossRef Pakish JB, Jazaeri AA. Immunotherapy in gynecologic cancers: are we there yet? Curr Treat Options Oncol. 2017;18(10):59.CrossRef
27.
go back to reference Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.CrossRef Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.CrossRef
28.
go back to reference Groisberg R, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5(1):100.CrossRef Groisberg R, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017;5(1):100.CrossRef
Metadata
Title
The immune microenvironment of uterine adenosarcomas
Authors
Ali Mohammed Refaat Ali
Jen-Wei Tsai
Cheuk Hong Leung
Heather Lin
Vinod Ravi
Anthony P. Conley
Alexander J. Lazar
Wei-Lien Wang
Michael J. Nathenson
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Sarcoma
Published in
Clinical Sarcoma Research / Issue 1/2020
Electronic ISSN: 2045-3329
DOI
https://doi.org/10.1186/s13569-020-0127-0

Other articles of this Issue 1/2020

Clinical Sarcoma Research 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine